Scratching the surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance.

Clinical data with enfortumab vedotin suggests that most bladder cancers overexpress NECTIN-4. A recent article shows that NECTIN-4 membranous expression changes with progression to metastatic disease and that low NECTIN-4 expression is potentially associated with EV resistance. These data argue for incorporation of NECTIN-4 expression into future biomarker strategies.